BR112022015002A2 - Ligante de il-7r-alfa/gama/c, composto, composição farmacêutica, método para tratar uma doença em um paciente e ácido nucleico - Google Patents
Ligante de il-7r-alfa/gama/c, composto, composição farmacêutica, método para tratar uma doença em um paciente e ácido nucleicoInfo
- Publication number
- BR112022015002A2 BR112022015002A2 BR112022015002A BR112022015002A BR112022015002A2 BR 112022015002 A2 BR112022015002 A2 BR 112022015002A2 BR 112022015002 A BR112022015002 A BR 112022015002A BR 112022015002 A BR112022015002 A BR 112022015002A BR 112022015002 A2 BR112022015002 A2 BR 112022015002A2
- Authority
- BR
- Brazil
- Prior art keywords
- gamma
- alpha
- ligand
- disease
- patient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5418—IL-7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062969432P | 2020-02-03 | 2020-02-03 | |
| US202063041158P | 2020-06-19 | 2020-06-19 | |
| PCT/US2021/016361 WO2021158623A1 (en) | 2020-02-03 | 2021-02-03 | IL-7Rαγc BINDING COMPOUNDS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022015002A2 true BR112022015002A2 (pt) | 2022-12-06 |
Family
ID=77200524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022015002A BR112022015002A2 (pt) | 2020-02-03 | 2021-02-03 | Ligante de il-7r-alfa/gama/c, composto, composição farmacêutica, método para tratar uma doença em um paciente e ácido nucleico |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11746139B2 (https=) |
| EP (1) | EP4100427A4 (https=) |
| JP (1) | JP2023514128A (https=) |
| KR (1) | KR20220139918A (https=) |
| CN (1) | CN115315435A (https=) |
| AU (2) | AU2021217353A1 (https=) |
| BR (1) | BR112022015002A2 (https=) |
| CA (1) | CA3166816A1 (https=) |
| IL (1) | IL295304A (https=) |
| MX (1) | MX2022009390A (https=) |
| TW (2) | TW202342505A (https=) |
| WO (1) | WO2021158623A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021001493A (es) | 2018-08-06 | 2021-07-15 | Medikine Inc | Compuestos de fijación al receptor de il-2. |
| KR20220110207A (ko) | 2019-11-05 | 2022-08-05 | 메디카인 인코포레이티드 | IL-2RβγC 결합 화합물 |
| MX2022005404A (es) | 2019-11-05 | 2022-09-09 | Medikine Inc | Compuestos de fijación a il-2r e il-7r dual. |
| JP2023512687A (ja) * | 2020-02-03 | 2023-03-28 | メディカイン、インコーポレイテッド | ＩＬ－７Ｒα結合化合物 |
| IL295304A (en) | 2020-02-03 | 2022-10-01 | Medikine Inc | Il-7 receptor alpha gamma c binding compounds, compositions comprising same and uses thereof |
| KR20230097168A (ko) * | 2020-11-04 | 2023-06-30 | 메디카인 인코포레이티드 | IL-2Rβγc 결합 화합물 및 이의 용도 |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| US11999771B2 (en) * | 2022-04-07 | 2024-06-04 | Medikine, Inc. | IL-7Rαγc ligand immunoglobulin fusion proteins |
| WO2024054870A1 (en) | 2022-09-06 | 2024-03-14 | Medikine, Inc. | Use of il-7r-alpha-gamma agonist peptides in cell manufacturing |
| US20240101959A1 (en) | 2022-09-06 | 2024-03-28 | Medikine, Inc. | Use of il-2r-beta-gamma agonist peptides in cell manufacturing |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635597A (en) | 1994-05-27 | 1997-06-03 | Affymax Technologies, N.V. | Peptides that bind IL-2 receptors |
| PT1454138E (pt) | 2001-12-04 | 2012-03-28 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| US20050054054A1 (en) * | 2002-11-12 | 2005-03-10 | Foss Francine M. | Interleukin-7 molecules with altered biological properties |
| CA2551915C (en) | 2003-12-30 | 2015-06-23 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Il-7 fusion proteins |
| CN101072793B (zh) | 2004-12-09 | 2012-06-20 | 默克专利有限公司 | 具有降低的免疫原性的il-7变体 |
| EP1828231A2 (en) | 2004-12-22 | 2007-09-05 | Novartis Vaccines and Diagnostics, Inc. | Group b streptococcus |
| WO2010099084A2 (en) | 2009-02-27 | 2010-09-02 | Monsanto Technology Llc | Isolated novel nucleic acid and protein molecules from corn and methods of using those molecules |
| ES2866674T3 (es) | 2010-11-12 | 2021-10-19 | Nektar Therapeutics | Conjugados de una fracción de IL-2 y un polímero |
| US9266937B2 (en) * | 2010-12-10 | 2016-02-23 | University Of Central Florida Research Foundation, Inc. | Compositions comprising IL-7 receptor ligands |
| HRP20200470T1 (hr) | 2011-01-18 | 2020-10-02 | Bioniz, Llc | Pripravci za modulaciju aktivnosti gama-c-citokina |
| WO2015164815A1 (en) | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| GB2538666A (en) | 2014-07-21 | 2016-11-23 | Delinia Inc | Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases |
| WO2016025385A1 (en) | 2014-08-11 | 2016-02-18 | Delinia, Inc. | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| PT3328894T (pt) | 2015-08-06 | 2019-02-13 | Agency Science Tech & Res | Anticorpos de cadeia comum gama/il2rbeta |
| SG11201803330WA (en) | 2015-10-22 | 2018-05-30 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| CA3011374A1 (en) | 2016-02-05 | 2017-08-10 | Washington University | Compositions and methods for targeted cytokine delivery |
| US11077172B2 (en) | 2016-11-08 | 2021-08-03 | Delinia, Inc. | IL-2 variants for the treatment of psoriasis |
| DK3551664T3 (da) | 2016-12-09 | 2021-05-03 | Ose Immunotherapeutics | Antistoffer og polypeptider rettet mod cd127 |
| BR122020025384B1 (pt) | 2016-12-13 | 2022-07-12 | Delinia, Inc | Proteínas de fusão e dimérica, usos das mesmas e composição farmacêutica |
| MX2021001493A (es) | 2018-08-06 | 2021-07-15 | Medikine Inc | Compuestos de fijación al receptor de il-2. |
| WO2020247388A2 (en) | 2019-06-03 | 2020-12-10 | Medikine, Inc. | Il-2alpha receptor subunit binding compounds |
| US20220119492A1 (en) | 2019-11-05 | 2022-04-21 | Medikine, Inc. | Il-2r-beta-gamma binding compounds and uses thereof |
| KR20220110207A (ko) | 2019-11-05 | 2022-08-05 | 메디카인 인코포레이티드 | IL-2RβγC 결합 화합물 |
| MX2022005404A (es) | 2019-11-05 | 2022-09-09 | Medikine Inc | Compuestos de fijación a il-2r e il-7r dual. |
| AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Bifunctional molecules comprising an IL-7 variant |
| JP2023512687A (ja) | 2020-02-03 | 2023-03-28 | メディカイン、インコーポレイテッド | ＩＬ－７Ｒα結合化合物 |
| IL295304A (en) | 2020-02-03 | 2022-10-01 | Medikine Inc | Il-7 receptor alpha gamma c binding compounds, compositions comprising same and uses thereof |
| KR20230097168A (ko) | 2020-11-04 | 2023-06-30 | 메디카인 인코포레이티드 | IL-2Rβγc 결합 화합물 및 이의 용도 |
| US11999771B2 (en) | 2022-04-07 | 2024-06-04 | Medikine, Inc. | IL-7Rαγc ligand immunoglobulin fusion proteins |
-
2021
- 2021-02-03 IL IL295304A patent/IL295304A/en unknown
- 2021-02-03 CN CN202180022881.5A patent/CN115315435A/zh not_active Withdrawn
- 2021-02-03 KR KR1020227030327A patent/KR20220139918A/ko not_active Withdrawn
- 2021-02-03 TW TW112126553A patent/TW202342505A/zh unknown
- 2021-02-03 MX MX2022009390A patent/MX2022009390A/es unknown
- 2021-02-03 EP EP21750982.7A patent/EP4100427A4/en not_active Withdrawn
- 2021-02-03 US US17/166,462 patent/US11746139B2/en active Active
- 2021-02-03 JP JP2022547164A patent/JP2023514128A/ja active Pending
- 2021-02-03 CA CA3166816A patent/CA3166816A1/en active Pending
- 2021-02-03 BR BR112022015002A patent/BR112022015002A2/pt not_active IP Right Cessation
- 2021-02-03 TW TW110104084A patent/TWI812918B/zh active
- 2021-02-03 WO PCT/US2021/016361 patent/WO2021158623A1/en not_active Ceased
- 2021-02-03 AU AU2021217353A patent/AU2021217353A1/en not_active Abandoned
-
2023
- 2023-07-11 US US18/350,543 patent/US11965015B2/en active Active
-
2024
- 2024-03-21 AU AU2024201860A patent/AU2024201860A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US11965015B2 (en) | 2024-04-23 |
| WO2021158623A1 (en) | 2021-08-12 |
| MX2022009390A (es) | 2022-11-16 |
| EP4100427A1 (en) | 2022-12-14 |
| US20210253670A1 (en) | 2021-08-19 |
| AU2021217353A1 (en) | 2022-08-25 |
| CN115315435A (zh) | 2022-11-08 |
| US11746139B2 (en) | 2023-09-05 |
| KR20220139918A (ko) | 2022-10-17 |
| AU2024201860A1 (en) | 2024-05-16 |
| EP4100427A4 (en) | 2024-01-17 |
| US20230357358A1 (en) | 2023-11-09 |
| JP2023514128A (ja) | 2023-04-05 |
| CA3166816A1 (en) | 2021-08-12 |
| IL295304A (en) | 2022-10-01 |
| TWI812918B (zh) | 2023-08-21 |
| TW202144390A (zh) | 2021-12-01 |
| TW202342505A (zh) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022015002A2 (pt) | Ligante de il-7r-alfa/gama/c, composto, composição farmacêutica, método para tratar uma doença em um paciente e ácido nucleico | |
| BR112022008744A2 (pt) | Ligante de il-2rss, ligante de il-2r¿c, composto de ligação a il-2r¿¿c, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método de uma terapia celular, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico | |
| BR112022008750A2 (pt) | Composto de ligação de receptor duplo, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico | |
| CL2024003895A1 (es) | Proteínas que se unen a nkg2d, flt3 y cd16; composición farmacéutica; y su uso. | |
| BR112021021224A2 (pt) | Anticorpos ou fragmentos de anticorpos, composição farmacêutica, kit, ácido nucleico ou conjunto de ácidos nucleicos, célula hospedeira recombinante e método para o tratamento ou a prevenção de uma doença em um paciente em necessidade do mesmo | |
| JOP20200315B1 (ar) | مركبات بورينون واستخدامها في معالجة السرطان | |
| BR112021024674A2 (pt) | Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo | |
| AR122018A1 (es) | Proteínas que se unen a nkg2d, cd16 y clec12a | |
| BRPI0622054B8 (pt) | composto e composição farmacêutica | |
| EA201991399A1 (ru) | Аминотриазолопиридиновые соединения и их применение в лечении рака | |
| BR112022024483A2 (pt) | Métodos para tratar mieloma múltiplo | |
| BR112022001324A2 (pt) | Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo | |
| BRPI0912411B8 (pt) | uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune | |
| BR112016002496A2 (pt) | composto de fórmula i, composição farmacêutica, método para inibição de kdm1a, método para tratamento de uma doença mediada por globina, método para atingir um efeito em um paciente, e, método para inibir pelo menos uma função de kdm1a | |
| EA200700501A1 (ru) | Композиция (варианты) и способ для лечения гиперпролиферативных процессов, способ лечения рака (варианты) и способ получения твёрдой дисперсии вещества | |
| ECSP066833A (es) | Compuestos heterocíclicos anticitocina | |
| EA201500373A1 (ru) | Маситиниб или его соль для лечения рака, фармацевтическая композиция, лекарственное средство и набор | |
| CO2024003967A2 (es) | Proteínas que se unen a nkg2d, cd16 y baff-r | |
| BR112020024412A8 (pt) | Anticorpos, composição farmacêutica, kit, ácido nucleico, célula hospedeira, métodos de tratamento ou prevenção de câncer, de redução da atividade, de aumento da atividade e de aumento da ativação | |
| MX2020002429A (es) | Compuestos para reducir la viscosidad de las formulaciones biologicas. | |
| MX2022014925A (es) | Moduladores de il-17a. | |
| JOP20200242A1 (ar) | مركبات البلاديينوليد واستخداماتها | |
| BR112022026550A2 (pt) | Composição de compostos que modulam o metabolismo celular e métodos de uso | |
| BR112023018237A2 (pt) | Fenalquilaminas e métodos para fabricação e uso das mesmas | |
| BR112013032911A2 (pt) | leucotoxina e/d como um novo agente anti-inflamatório e microbicida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2865 DE 02-12-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |